Evaluation of thrombospondin 1 as a novel biomarker in pediatric-onset systemic lupus erythematosus.

ABSTRACT:

Objective

This study aimed to assess the potential of thrombospondin 1 (TBS-1) as a biomarker for pediatric-onset systemic lupus erythematosus (pSLE) and investigated its association with clinical characteristics and other laboratory tests in pSLE.

Methods

A total of 112 pSLE and 50 age-matched and gender-matched healthy controls (HCs) were recruited in this study from January 2022 to June 2023 at West China Second University Hospital, Sichuan university. Plasma TBS-1 levels were measured, and clinical and laboratory findings were collected from the medical database.

Results

The plasma TBS-1 level was significantly lower in pSLE patients (26778 ng/mL, IQR: 9875-59011) compared to HCs (100583 ng/mL, IQR: 58327-189547) (P < 0.0001). ROC analysis demonstrated that TBS-1

SUBMITTER: Liu C 

PROVIDER: S-EPMC11905435 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature